SCHEMBL810244

SCHEMBL810244

Cc1ccc2c(Nc3cc(OCc4ccc5ccccc5n4)ccc3Sc3ccc(O)cc3)ncnc2n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.72
AKT2 P31751 1/20 0.72
CYSLTR1 Q9Y271 7/20 0.41
GPBAR1 Q8TDU6 6/20 0.41
CYSLTR2 Q9NS75 1/20 0.41
PDE10A Q9Y233 4/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
KDR P35968 1/20 0.39
CYP1A2 P05177 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810799 0.88 PIM1 (0.75) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL810532 0.87 PIM1 (0.79) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL810706 0.86 PIM1 (0.71) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL811263 0.85 PIM1 (0.82) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL810908 0.85 PIM1 (0.85) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL811393 0.84 PIM1 (1.00) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL811128 0.84 PIM1 (0.74) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL810188 0.83 PIM1 (0.73) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL810707 0.83 PIM1 (0.73) PIM1AKT2MEN1MAPTKMT2A
SCHEMBL810332 0.83 PIM1 (0.72) PIM1AKT2MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
US-8236950-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-08-07 US disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-20110160233-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 US disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-2094276-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2009-09-02 EP disclosed
WO-2008133753-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2008-11-06 WO disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160233-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885CYSLTR1 4364/4885
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885CYSLTR1 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.